|
Daniel's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Elevar secures its first FDA approval, Ondine reports Steriwave phase III data, and ACROBiosystems unveils AI and biopharma supply-chain tools.
The top 10 stories from Thu Sep 24, 2026 07:07 AM to Fri Sep 25, 2026 07:07 AM
Generated September 25, 2026 at 7:07 AM
|
|
|
#1 Backed by NVIDIA and Anthropic, Basecamp bags $140M to advance AI-designed drugs Published 2026-09-24 Basecamp Research raised $140 million from investors including NVIDIA and Anthropic to advance AI-designed drugs. Covered by: biospace.com, biocentury.com |
#2 RNAi drug specialist ADARx raises $446M IPO Published 2026-09-25 RNAi drug developer ADARx raised $446 million in its U.S. initial public offering, becoming the first RNAi biotech to price an IPO there in over a decade. Covered by: biopharmadive.com |
#3 Roche secures separate discovery deals with Atavistik, Earendil Published 2026-09-24 Roche has entered separate drug-discovery partnerships with Atavistik Bio and Earendil Labs, extending its recent dealmaking activity. Covered by: endpoints.news, prnewswire.com |
#4 Kasvu All Set To Advance New Class In Depression Published 2026-09-24 Kasvu, led by Matti Karvonen, Jami Mandelin, and Georgios Trichas, is preparing to advance a new depression treatment class. Covered by: insights.citeline.com |
#5 Ondine’s Steriwave: Will New Antimicrobial Development Finally Be Rewarded With Commercial Success? Published 2026-09-24 Ondine Biomedical published phase III topline data for Steriwave, a drug-device technology designed to reduce surgical-site infections. Covered by: insights.citeline.com |
#6 Renibus Therapeutics Announces Participation at the Oppenheimer Private Life Sciences Company Showcase Published 2026-09-24 Renibus Therapeutics announced its participation in the Oppenheimer Private Life Sciences Company Showcase. Covered by: prnewswire.com |
#7 Elevar wins first FDA approval with second-line drug for bile duct cancer Published 2026-09-24 The FDA approved Elevar Therapeutics’ Lyrfigtu as a second-line treatment for certain bile duct cancer patients, marking the company’s first approval. Covered by: endpoints.news |
#8 ACROBiosystems Introduces CHO-Direct and ACRO AIx to Accelerate AI-driven Drug Discovery Published 2026-09-24 ACROBiosystems introduced ACRO AIx, CHO-Direct, and GlobalLifeShip, targeting AI-driven drug discovery and cross-border biopharmaceutical supply chains. Covered by: prnewswire.com |
#9 Network Bio: Building disease-specific AI models with biobank data Published 2026-09-25 Palo Alto-based Network Bio uses patient-derived tissue biobank data to develop disease-specific AI models aimed at tracking disease progression and enabling earlier detection and treatment. Covered by: biocentury.com |
#10 Merck’s Wnt Agonist Is Efficacious As New Mechanism For Eye Disease Published 2026-09-24 Merck’s remigromig matched Lucentis in a Phase IIb/III diabetic macular edema trial but had higher rates of safety issues. Covered by: insights.citeline.com |
